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Abstract
Introduction: Fresh frozen plasma (FFP) is widely used, but few studies have described patterns of plasma use in
critical care. We carried out a multicentre study of coagulopathy in intensive care units (ICUs) and here describe
overall FFP utilisation in adult critical care, the indications for transfusions, factors indicating the doses used and
the effects of FFP use on coagulation.
Methods: We conducted a prospective, multicentre, observational study of all patients sequentially admitted to 29
adult UK general ICUs over 8 weeks. Daily data throughout ICU admission were collected concerning coagulation,
relevant clinical outcomes (including bleeding), coagulopathy (defined as international normalised ratio (INR) >1.5,
or equivalent prothrombin time (PT)), FFP and cryoprecipitate use and indications for transfusion.
Results: Of 1,923 admissions, 12.7% received FFP in the ICU during 404 FFP treatment episodes (1,212 FFP
units). Overall, 0.63 FFP units/ICU admission were transfused (0.11 units/ICU day). Reasons for FFP transfusion
were bleeding (48%), preprocedural prophylaxis (15%) and prophylaxis without planned procedure (36%).
Overall, the median FFP dose was 10.8 ml kg
-1, but doses varied widely (first to third quartile, 7.2 to 14.4 ml
kg
-1). Thirty-one percent of FFP treatments were to patients without PT prolongation, and 41% were to
patients without recorded bleeding and only mildly deranged INR (<2.5). Higher volumes of FFP were
administered when the indication was bleeding (median doses: bleeding 11.1 ml kg
-1,p r e p r o c e d u r a l
prophylaxis 9.8 ml kg
-1, prophylaxis without procedure 8.9 ml kg
-1; P = 0.009 across groups) and when the
pretransfusion INR was higher (ranging from median dose 8.9 ml kg
-1 at INR ≤1.5 to 15.7 ml kg
-1 at INR >3;
P < 0.001 across ranges). Regression analyses suggested bleeding was the strongest predictor of higher FFP
dose. Pretransfusion INR was more frequently normal when the transfusion indication was bleeding. Overall,
posttransfusion corrections of INR were consistently small unless the pretransfusion INR was >2.5, but
administration during bleeding was associated with greater INR corrections.
Conclusions: There is wide variation in FFP use by ICU clinicians, and a high proportion of current FFP transfusions
are of unproven clinical benefit. Better evidence from clinical trials could significantly alter patterns of use and
modify current treatment costs.
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Fresh frozen plasma (FFP) and cryoprecipitate are used
widely in hospital practice across a range of clinical spe-
cialties, especially in critical care units [1-5]. FFP is pre-
scribed for two main indications: first, to prevent
bleeding (prophylaxis), and second, to stop bleeding
(therapeutic). However, there are few detailed, prospec-
tive, descriptive data from large studies describing these
patterns of use in the critically ill. FFP is associated with
well-recognised risks [6,7], some of which are probably
underrecognised, such as transfusion-associated lung
injury and transfusion-associated circulatory overload
[8-13]. Moreover, recent concerns that red cell transfu-
sion may adversely affect clinical outcomes raises con-
cerns that other blood components may not always
benefit patients [14-17].
We previously reported a large national study of coa-
gulopathy in UK intensive care units (ICUs), which
showed that 30% of all critical care admissions had at
least one episode of prothrombin time (PT) prolonga-
tion [18]. We described risk factors for the development
of coagulopathy and showed an association with higher
ICU mortality, but did not describe the use of FFP in
detail. The aim of this analysis of the study database
was to describe plasma use in detail, with the following
research questions. (1) What reasons do clinicians give
for administering FFP, and how does the presence of
bleeding and coagulopathy influence the dose? (2) What
PT or international normalised ratio (PT/INR) triggers
are currently used by clinicians, and how do these relate
to the doses administered? (3) What changes in PT/INR
occur following FFP administration? We also describe
the current use of cryoprecipitate in UK critical care,
since it is often prescribed with or as an alternative to
FFP.
Materials and methods
A detailed description of the Intensive Care Study of
Coagulopathy (ISOC study) has been previously pub-
lished [18]. ISOC was a prospective observational cohort
study of sequential patients admitted to 29 ICUs in
Scotland, England, Northern Ireland and Wales. ICUs
were mixed general units and did not include specialist
cardiac centres. All admissions were eligible for inclu-
sion, with the exception of readmissions during the
same hospital stay and patients with short life expec-
tancy (under 4 hours). The study was observational, and
only routinely available clinical data were recorded. The
ethics committee waived the need for patient consent
(Lothian Research Ethics Committee).
Data were collected prospectively from patient records
for the 24 hours prior to admission and every subse-
quent day in the ICU until discharge, death or 30 days
(for patients remaining in the ICU at this time). Data
collected included haematology and coagulation test
results, all procedures, the occurrence of clinically
significant haemorrhage during each 24-hour period
(defined as estimated total cumulative blood loss
>300 ml, 1 U of red cells or bleeding from a critical site,
such as intracranial, as defined in the Audit of Transfu-
sion in Intensive Care in Scotland study [19]), and all
blood component transfusions. The timing of FFP trans-
fusion was recorded, and the reasons for FFP were clas-
sified by clinical staff into four categories: ‘coagulopathy
with bleeding’, ‘coagulopathy with no bleeding’, ‘coagu-
lopathy with no bleeding prior to an invasive procedure’
or ‘other’. An additional data collection form was com-
pleted on the first day that a patient developed labora-
tory evidence of coagulopathy (defined below) and
included a range of variables predefined by consensus
by the investigators as potential factors that might influ-
ence the occurrence of coagulopathy.
All data were scanned into a database using the Read-
Soft system (’Eyes and Hand’, Readsoft Ltd, Milton Key-
nes, UK), and quality control procedures included
computer-based sense checking, manual checking of all
queries and resolution of data queries by research staff
in individual ICUs when necessary.
The definition of coagulopathy was based on a labora-
tory threshold INR value >1.5 or an equivalent PT
beyond local reference range. Around one-half of parti-
cipating ICUs reported results as PTs and one-half
reported them as INRs. We therefore converted data to
an INR value using the local International Specificity
Index (ISI) for the laboratory, which enabled compari-
son across all ICUs.
Analysis
We have previously described in detail the epidemiology
of PT prolongation for the cohort, including prevalence,
risk factors, severity and relationship to ICU mortality
[18]. The present analysisi sf o c u s s e do nad e t a i l e d
description of FFP use, but we also describe the use of
cryoprecipitate as, in the UK, both components tend to
be used to manage PT prolongation. Prothrombin com-
plex concentrates and fibrinogen concentrate are not in
routine clinical use for the management of coagulopathy
in the critically ill.
Use of FFP
We calculated the proportion of patients who received
FFP during their ICU stay and the number of units
transfused. Overall FFP use in critical care was calcu-
lated per ICU admission and per ICU day. The duration
of an episode of PT prolongation was defined as the
time between the first recorded point when the INR was
>1.5 until the first recorded INR ≤1.5 without FFP
transfusion support for 12 hours. An FFP treatment epi-
sode was defined as including all units of FFP where the
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was 2 hours or less. FFP transfusion episodes were
reported per patient and assessed by the INR values pre-
ceding transfusion and by the degree of correction up to
6, 12 or 24 hours after transfusion. We used the esti-
mated patient weight recorded for each patient to calcu-
late the dose of FFP administered for each FFP
transfusion episode in milligrams per kilogram.
Dose of FFP and reason for administration
We plotted the distribution of dose of FFP administered
as a histogram and calculated the median (first to third
quartiles) dose administered overall, and according to
the INR value preceding transfusion and the clinical
indication given for transfusion. We used three
approaches to describe the reasons for FFP transfusion
episodes. First, we used the reason recorded at the time
of FFP transfusion by clinicians (see above). Second, we
used the binary data field recorded each day, asking
whether a clinically significant haemorrhage had
occurred to classify each FFP transfusion episode as
associated with bleeding or not. Third, each FFP trans-
fusion episode was categorised according to whether it
occurred either in a patient who had no episodes of PT
prolongation documented during ICU stay, or during an
episode of PT prolongation or outside an episode of PT
prolongation but in a patient who experienced PT pro-
longation at some other time during their ICU stay.
We calculated the volume of FFP used for each of the
above-defined categories and presented these data as
medians (first to third quartiles) for volume, FFP units
and volume per estimated patient weight. The Kruskal-
Wallis test was used to compare FFP use for the various
approaches for classifying the reason for FFP transfu-
sion. A regression model was also undertaken, using
FFP volume as the dependent variable, to explore the
relative association of the three methods described
above for categorising reasons for FFP transfusion
simultaneously, and allowing for possible correlation
within patients.
INR values pre-FFP transfusion
We used the INR preceding each FFP transfusion epi-
sode as an indicator of the “INR trigger” and recorded
the frequency in ranges of INR for all FFP transfusion
episodes for each of the clinical indication categories
and for FFP transfusions administered on days with sig-
nificant bleeding or no bleeding. INR values were com-
pared across these categories using c
2 tests. The volume
of FFP transfusion in relation to the INR preceding
transfusion was calculated and compared using c
2 tests.
Change in INR post-FFP transfusion
We calculated the proportion of patients who had an INR
value rechecked within 24 hours of FFP transfusion, and
the distribution of times from FFP transfusion to
rechecking coagulation status. For FFP transfusions with
a repeat INR recorded within 24 hours, we calculated the
change from pre- to post-FFP transfusion to describe the
correction of INR that occurred using the pretransfusion
INR to assess change, assuming a value was recorded
during the 12 hours prior to FFP transfusion. We
explored changes in INR values for different pretransfu-
sion INR values. To do this with appropriate adjustment
for potential confounding, an analysis was performed to
model the change in INR level in relation to the variables
of pretreatment INR, dose of FFP, indication for treat-
ment and time after transfusion to INR measurement
using the following approach. In an initial stage, the
effect of regression to the mean of INR levels was allowed
for. We acknowledged that pretreatment INR might be
associated with the indication for treatment and FFP
dose, so, to avoid confounding, the pretreatment INR
was initially regressed on these variables and the residuals
were used to produce an adjusted pretreatment INR. The
posttreatment INR was then regressed on the adjusted
pretreatment level to allow for regression to the mean.
The residuals from this regression, when added to the
mean posttreatment INR, gave the adjusted posttreat-
ment INR, or, when added to the mean change in INR,
gave the adjusted change in INR. This in turn was
regressed on the dose of FFP, the indication for treatment
and the time after infusion to performing INR measure-
ment to produce the required analysis.
Cryoprecipitate use
We calculated the proportion of patients who received
cryoprecipitate during the 24 hours prior to and during
ICU stay. The distribution of cryoprecipitate use was
evaluated by indication and for patients with documen-
ted bleeding. Transfusions of cryoprecipitate were
assessed by fibrinogen values preceding transfusion and
by the degree of correction up to 24 hours after
transfusion.
Results
Use of FFP
Of 1,923 admissions during the study period, 12.7% (244
patients) received FFP in the ICU. These patients
received 404 FFP treatment episodes comprising 1,212
units of FFP (or an average 5 U of FFP/transfused
patient). For all ICU admissions, this represented a rate
of 0.11 U of FFP/ICU day and 0.63 U of FFP/ICU
admission. A total of 576 (30%) patients had episodes of
coagulopathy defined by PT prolongation, of whom 188
(33%) received transfused FFP. These patients received
86% (1,037 of 1,212) of the total FFP units administered
during the study period.
Dose of FFP and reason for administration
A wide range of FFP treatment doses were administered
(Figure 1). Overall a median (first to third quartile;
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administered per episode, which equated to a median
10.8 ml kg
-1 (7.2 to 14.4; 2.4 to 41.1 ml kg
-1). A propor-
tion of 69% (277 of 404) of FFP treatments were admi-
nistered during episodes of PT prolongation, comprising
71% (856 of 1,212) of the total FFP transfused. A signifi-
cant proportion (31%) was administered to patients who
had no PT prolongation at the time of transfusion.
A clinical indication for FFP transfusion was recorded
for 388 (96%) of 404 FFP treatment episodes. The rea-
son was documented as bleeding for 48% of episodes,
prophylaxis for a procedure for 15%, and in 36% of
cases no procedure was planned and no bleeding was
documented as being present. Six treatments were given
for other reasons (1.5%). The doses of FFP administered
in relation to the three approaches to classifying the cir-
cumstances of administration are shown in Table 1. On
the basis of the reasons given by clinicians for adminis-
tering FFP, on average 1 FFP unit more (approximately
300 ml) was administered when clinicians stated the
indication was bleeding compared with a nonbleeding
indication (P < 0.0001). On the basis of the association
with recorded clinically significant bleeding on daily
charts, haemorrhage was recorded in 258 (13%) of 1,923
patient admissions on a total of 410 patient days, and
most frequently affected the gastrointestinal tract, chest,
and abdominal cavity. Clinically significant haemorrhage
was recorded on the day of FFP transfusion for 47% of
FFP transfusion episodes, which was virtually identical
to the clinical classification documented. This analysis
confirmed that when bleeding was present, on average,
1 FFP unit more (300 ml; 2 ml kg
-1) was administered
than when no bleeding was documented (Table 1) (P <
0.0001). This difference was even more marked when all
FFP treatments administered on a calendar day on
which bleeding was documented were included (median
FFP dose 14.4 ml kg
-1 (9.1 to 24.9; range, 2.4 to 54.8).
When FFP use was classified according to the presence
of prolongation of INR, higher volumes of FFP were
administered during episodes of INR prolongation com-
pared with transfusions given at other times or to
patients who never had documented INR prolongation
(Table 1).
In the regression model, using volume given as the
dependent variable and allowing for all of these three
categorisations simultaneously and for possible correla-
tion within patients, there was no interaction between
these factors in predicting the FFP volume administered.
In an additive model, the reason given by the clinician
(bleeding) had the strongest association with the FFP
volume administered (P = 0.02), with weaker associa-
tions found with the relationship to coagulopathy (P =
0.08) and occurrence of haemorrhage on the day of
transfusion (P = 0.20).
Figure 1 Doses of fresh frozen plasma administered. Graphed histogram results summarising the range of doses of fresh frozen plasma (FFP)
given in treatment episodes during intensive care unit (ICU) stay.
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An INR value preceding FFP transfusion (within 12
hours) was available for 90% (362 of 404) of episodes
and varied widely as reported for INR (Table 2). A
high proportion of all FFP treatments were adminis-
tered to patients without clinical evidence of bleeding
and with either no or minor INR prolongation prior to
transfusion (Table 2). For example, 40% of all FFP
treatments were given to patients without recorded
bleeding whose preceding INR was <2.5, and for 8.6%
of all treatments there was no haemorrhage and the
preceding INR was <1.5. When we used recorded,
clinically significant haemorrhage on the day of FFP
transfusion to dichotomise the population, a similar
pattern was seen: 41% of FFP transfusions were given
to patients with no bleeding on the day of transfusion
and a pretransfusion INR of <2.5, and 8% were given
to patients with INR <1.5.
Comparing FFP transfusions for which the clinical
indication was recorded as coagulopathy plus bleeding
with the nonbleeding categories indicated that pretrans-
f u s i o nI N Rv a l u e sw e r em o r ef r e q u e n t l ye i t h e rn o r m a l
or only mildly prolonged when bleeding was present
(P = 0.006; c
2 test). A similar pattern was observed
when FFP transfusions administered on days with clini-
cally significant haemorrhage were compared with those
administered on days with no recorded haemorrhage
(P = 0.002). These data show that although a high pro-
portion of FFP treatments associated with bleeding were
preceded by normal or mildly prolonged INR, as might
Table 2 INR preceding (within 12 hours) FFP treatment during ICU stay for all admissions
a
INR
Variable ≤1.5, n (%) 1.6 to 2.5, n (%) 2.6 to 3.5, n (%) 3.6 to 5.0, n (%) >5.0, n (%)
All episodes, n (%) 126 (34) 187 (51) 30 (8) 14 (4) 9 (2)
Reason for FFP transfusion recorded by clinician
Coagulopathy with bleeding 73 (42) 86 (50) 8 (5) 2 (1) 4 (2)
Coagulopathy without bleeding 32 (26) 65 (52) 15 (12) 9 (7) 4 (3)
Coagulopathy without bleeding,
prior to invasive procedure
13 (25) 29 (56) 7 (13) 2 (4) 1 (2)
Clinically significant haemorrhage recorded on same day as FFP transfusion
No 54 (29) 95 (51) 20 (11) 12 (6) 6 (3)
Yes 72 (40) 92 (51) 10 (6) 2 (1) 3 (2)
aINR, international normalised ratio; FFP, fresh frozen plasma; ICU, intensive care unit.
Table 1 FFP administered in relation to the three approaches to classifying the circumstances of administration
a
Variable FFP units
(median, first to
third quartile)
FFP volume, ml
(median, first to
third quartile)
FFP dose, ml kg
-1
(median, first to
third quartile)
Reason given by clinician at time of FFP transfusion
Coagulopathy with bleeding (n = 185) 3 (2 to 4) 875 (558 to 1104) 11.1 (7.8 to 15.3)
Coagulopathy without bleeding (n = 138) 2 (2 to 4) 561 (509 to 854) 8.9 (6.8 to 13.1)
No bleeding prior to procedure (n = 59) 2 (2 to 4) 560 (528 to 1017) 9.8 (6.9 to 13.0)
P value for differences across groups <0.0001 <0.0001 0.009
All (N = 404) 3 (2 to 4) 736 (536 to 1092) 10.2 (7.0 to 14.1)
Clinically significant haemorrhage recorded on day of transfusion
No (n = 215) 2 (2 to 4) 561 (517 to 1017) 9.1 (6.7 to 13.2)
Yes (n = 189) 3 (2 to 4) 875 (558 to 1100) 11.1 (7.9 to 14.7)
P value for differences across groups <0.0001 <0.0001 0.006
Use of FFP in relation to occurrence of PT prolongation during ICU admission
FFP administered but no PT prolongation occurred at any time during ICU
admission (n = 64)
2 (2 to 4) 568 (502 to 936) 8.5 (5.7 to 12.6)
PT prolongation occurred during ICU admission, but FFP administered out
with an episode of PT prolongation (n = 63)
2 (2 to 4) 570 (535 to 1077) 8.6 (6.3 to 13.7)
FFP administered during an episode of PT prolongation (n = 277) 3 (2 to 4) 806 (542 to 1092) 10.8 (7.3 to 14.4)
P value for differences across groups 0.11 0.037 0.014
aFFP, fresh frozen plasma; PT, prothrombin time; ICU, intensive care unit.
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ture of prophylactic or preprocedural transfusions.
Smaller doses of FFP were administered to patients
when the transfusion was given outside episodes of PT
prolongation (median 570 ml) or in patients who never
had PT prolongation (median 568 ml) (Table 1). The
dose of FFP administered in relation to increasing pre-
transfusion INR is shown in Table 3, which confirmed
the trend for FFP dose to increase with higher INR
value. There were 56 patients who received 64 FFP
treatments in the ICU but never had documented INR
prolongation at any stage. Clinical factors for this group
have been reported previously [18]. To also explore the
potential importance of activated partial thromboplastin
time (APTT) values, we extracted the APTT value prior
to FFP transfusion. For 24 of these 64 treatments, no
APTT value was measured during the 24 hours prior to
FFP administration, and for the other 40 treatments,
APTT was measured but was only mildly prolonged in
most cases (median APTT value 42 seconds (interquar-
tile range 33.5 to 51.5 seconds)).
Change in INR following FFP transfusion
A posttransfusion INR was available within 6 hours for
68% (n = 276) of FFP transfusions (76% when the reason
for transfusion was bleeding, 62% when bleeding was
not recorded as the reason and 56% when the reason
was prior to invasive procedures). Ninety-three percent
(n = 375) of patients receiving FFP had a repeat INR
checked within 24 hours. For FFP transfusions with a
repeat INR available within 6 hours, the pre- to post-
transfusion INR changes are illustrated in Figure 2. As
expected, the median reductions in INR were greater
when the pre-FFP transfusion values were higher (med-
ian change -0.1, -0.4, -1.0 and -2.5 for pretransfusion
INRs in the ranges 1 to ≤1.5, 1.6 to 2.5, 2.6 to 3.5 and
>3.5, respectively).
In univariate analyses, we found no relationship
between degree of change of INR and dose of FFP used
(P = 0.86). In the multivariable regression analysis
designed to allow for regression to the mean, which
included changes in INR across the three clinical cate-
gories (’coagulopathy with bleeding’, ‘coagulopathy with
no bleeding’ and ‘coagulopathy with no bleeding prior
to an invasive procedure’) in relation to the dose of FFP
administered, and taking into account relationships with
pretransfusion INR, we found that the posttransfusion
INRs were 0.2 (SE ±0.05) lower when FFP was given for
bleeding compared to the other clinical indications.
The INR was found to rise significantly with time fol-
lowing the first posttransfusion INR, with a mean
increase of 0.3 (SE ±0.1) over a 24-hour period.
Use of cryoprecipitate
Transfusion of cryoprecipitate during ICU stay was
recorded in only 62 of 1,923 admissions (3%) and was
more frequent in admissions with INR prolongation (50
(9%) of 576 vs. 12 (1%) of 1,347). These 62 patients
received 69 cryoprecipitate transfusions, most of which
(46 patients; 67%) were associated with clinically signifi-
cant bleeds on the same day or in the previous 24
hours. FFP was administered on 41 of these 46 occa-
sions and was also administered on 17 of the 23 transfu-
sion days that were not associated with bleeding. Pre-
and postcryoprecipitate transfusion fibrinogen values
were available for 35 of the 46 patients in whom hae-
morrhage was documented. The mean fibrinogen con-
centration prior to cryoprecipitate transfusion was 1.62
g/l (SD ±1.06) and increased to a mean of 2.89 g/l (SD
±1.67) (mean increase of 1.27 g/l (SD ±1.80)). In total,
during the ICU stay, there were 7,208 fibrinogen tests
on 5,970 patient-days from 1,391 patients [18]. Ninety-
eight of the 7,208 fibrinogen tests performed in total
gave a fibrinogen level <1 g/dl (1.4%).
Discussion
This pragmatic national epidemiological study of admis-
sions to general ICUs in the UK indicated that 13% of
all patients admitted received FFP. There was wide var-
iation in the dose used, even after we classified transfu-
sion episodes according to the reasons given by
clinicians, the presence of bleeding and the presence of
coagulopathy defined by INR prolongation. A remark-
ably high proportion of FFP was administered to
patients without evidence of bleeding, and many of
these patients had normal or only mildly deranged INR
values. For example, 40% of all FFP treatments were
administered to patients without haemorrhage and in
whom preceding coagulation tests were normal or only
modestly deranged (INR ≤2.5), and 29% of FFP treat-
ments were administered outside episodes of INR pro-
longation. Relevant clinical factors to describe the
epidemiology of these subgroups of coagulopathy in cri-
tical care have been described previously [18], but our
data in this paper extend these findings and illustrate
Table 3 Median (first to third quartile) FFP dose (ml/kg)
administered for different pretransfusion INR values
a
INR value preceding
FFP treatment
Median FFP dose per treatment, ml/kg
(first to third quartile)
≤1.5 8.9 (5.8 to 13.9)
1.6 to 2.0 9.7 (6.7 to 15.3)
2.1 to 2.5 13.8 (8.6 to 18.7)
2.6 to 3.0 13.7 (7.8 to 24.2)
>3.0 15.7 (11.4 to 22.1)
aFFP, fresh frozen plasma; INR, international normalised ratio. Results for FFP
dose administered by level of pretransfusion INR are shown. P < 0.001 across
the groups (Kruskal-Wallis test).
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tration, which must raise questions about the appropri-
ateness of use and effectiveness of FFP.
We found that clinicians prescribed marginally
higher volumes of FFP in association with bleeding
and when the INR was prolonged, and our regression
model found haemorrhage to be the clinical indication
that was the strongest factor in predicting higher
transfusion volume. However, typically only around
one additional unit of FFP was administered per trans-
fusion episode under these circumstances, with a med-
ian volume transfused of about 11 ml/kg. Current
guidelines support the need for adequate doses of FFP
to achieve haemostasis, typically 10 to 1 ml/kg [20,21],
but even these doses of FFP may fail to correct low
coagulation factor levels without taking into considera-
tion factors such as the size of the patient, the extent
of coagulation deficiency or the degree of abnormality
to be corrected [2,22].
Our data suggest that under circumstances where FFP
has a higher probability of patient benefit, namely,
bleeding in a patient with INR prolongation, inadequate
doses are currently administered to reliably correct coa-
gulation factor deficiencies. This may explain, in part,
the small decreases in INR prolongation that we
observed after FFP transfusion, especially when the INR
w a so n l ym o d e s t l yp r o l o n g e d[ 2 , 2 3 , 2 4 ] .V a r i a b l er e d u c -
tions in INR may also be explained by differences in the
time taken for rechecking INR after FFP transfusion,
although our statistical model incorporated this variable.
The reasons for transfusion of inadequate volumes of
FFP are unclear and require further investigation. In
addition, an understanding of the nonlinear relationship
between coagulation factor content and INR would also
indicate why, with minimally deranged prolongations in
INR, the effects of FFP transfusion aimed at raising the
levels of coagulation factors and reducing the INR are
likely to be very small [25]. If inadequate FFP adminis-
tration influences clinical outcomes during bleeding, as
is suggested by emerging evidence relating to trauma-
associated coagulopathy and massive haemorrhage
[26,27], the variation and inconsistent practice we have
documented could affect clinical outcomes.
Conversely, the large number of FFP transfusions
administered to nonbleeding patients without INR pro-
longation or with minor derangements suggests the pos-
sibility of widespread and inconsistent use of FFP
without strong clinical rationale. Recent systematic
Figure 2 Effects of fresh frozen plasma on changes in international normalised ratio. Boxplot summarising the changes in international
normalised ratio (INR), which are shown as medians (horizontal line), first and third quartiles (squares) and ranges (vertical lines) with outliers
indicated by small circles or asterisks. The results are reported by reason for fresh frozen plasma (FFP) transfusion recorded by clinician
(coagulopathy with bleeding, coagulopathy without bleeding or coagulopathy without bleeding prior to invasive procedure) for different levels
of pretransfusion INR.
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including the poor predictive value of standard coagula-
tion tests, and no clear benefit of prophylactic use or to
reduce bleeding related to planned procedures [28,29].
Indeed, available data suggest that many patients with
isolated minor abnormalities in PT or INR have ade-
quate individual coagulation factor levels, which would
be consistent with our data [30]. Furthermore, the FFP
volumes administered in these nonbleeding situations
were 9 ml/kg or less in more than 50% of cases, and
t h e s ed o s e sa r eh i g h l yu n l i k e l yt or e s u l ti nc o n s i s t e n t
increases (if any) in coagulation factor levels if deficien-
cies do exist [2,22-25]. Our data show that critical care
clinicians in the UK continue to use FFP widely in this
prophylactic situation, with evidence of insignificant
changes in the INR value [2,31].
Stronger evidence is needed to guide clinicians. Speci-
fically, evidence suggesting that correction of INR pro-
longation is not required in the prophylactic clinical
situation could significantly alter current practice and
potentially reduce demand for FFP. Continuing reports
of an association between FFP administration and
adverse patient outcomes in patients, including the criti-
cally ill, further emphasise the requirement to improve
the evidence base, especially for transfusion of FFP to
nonbleeding patients [6,9-13,32-35].
Our population estimates found that 0.63 FFP units/
ICU admission were utilised in UK general critical care
units, which equates to approximately 63,000 units/year,
based on the 100,000 patients admitted to general ICUs
in the UK each year. This comprises around 21% of the
total FFP used in the UK and, of note, excludes cardiac
ICUs, which were not included in our study. On the
basis of our estimates of the proportion used in non-
bleeding patients with normal or mildly deranged INRs
(<2.5), who received 40% of FFP treatments, and our
observed median use for this indication of 2 FFP units/
transfusion episode, we estimate that about 40,000 units
are transfused each year to patients in whom the evi-
dence base for benefit is weak. These estimates illustrate
the potential impact of an improved evidence base, par-
ticularly if this evidence supports more restrictive use.
The potential cost implications of introducing newer
products, such as factor complex concentrates or patho-
gen-inactivated plasma, are also unclear in the absence
of evidence of benefit for the standard product.
There are limitations to our pragmatic study. Around
one-half of the participating ICUs reported coagulation
results as PT and one-half reported them as INRs. The
definition of coagulopathy was based on PT prolongation
and a threshold INR value >1.5. This cutoff level is com-
monly used by clinicians and described in the literature
[19,21,36], and the use of the INR allowed the data to be
compared and standardised across the ICUs, which
would not be possible for the PT, given that laboratories
use different thromboplastins with different laboratory-
specific mean normal PT and ISI. However, the PT was
developed to assess coagulation factor deficiencies, and
the INR was developed to standardise assessment of the
response to vitamin K antagonists [36,37]. For our pri-
mary analysis, we did not relate FFP use to APTT, which
could also trigger correction of coagulation, especially in
relation to bleeding. To explore the potential importance
of APTT values, we examined the 56 patients who
received 64 FFP treatments but never had documented
PT prolongation during their ICU stay, and then
extracted the APTT value prior to FFP transfusion. The
results did not suggest that APTT prolongation was likely
to explain the widespread use of FFP when the INR was
normal or mildly prolonged, although our study was not
designed to answer this question.
Conclusions
FFP continues to be widely used as a prophylactic or
precautionary treatment in critically ill nonbleeding
patients with mild coagulation abnormalities. Wide var-
iation in clinical use exists in terms of indication and
the dose used, which is often inadequate to reliably
increase individual factor levels. Our data support the
need for more research to improve the current under-
standing of the risk-to-benefit profile of plasma therapy,
and specifically the need (if at all) for FFP or other pro-
ducts, especially in relation to nonbleeding patients.
Key messages
￿ FFP is widely used, but there are few data from pro-
spective studies describing patterns of plasma use in cri-
tical care.
￿ In this national prospective study, of 1,923 admis-
sions to adult critical care, 12.7% received FFP in the
ICU during 404 FFP treatment episodes (1,212 FFP
units).
￿ Thirty-one percent of FFP treatments were adminis-
tered to patients without PT prolongation, and 41%
were given to patients without recorded bleeding and
only mildly deranged INRs (<2.5).
￿ Overall, posttransfusion corrections of INR were con-
sistently small unless the pretransfusion INR was >2.5.
￿ There is wide variation in FFP use by ICU clinicians,
and a high proportion of current FFP transfusions are of
uncertain and unproven clinical benefit.
Abbreviations
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